IRD News

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

Roche has two FDA catalysts coming up for Tecentriq and Enspryng, while Viatris and Opus Genetics await a decision on expanding MR-141 into the presbyopia market.

The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: a great company can get crushed by bad news somewhere else in the pipeline. A Novartis (NYSE:NVS) setback rippled through the biotech space, yesterday, dragging down companies whose own announcements were positive.

Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study

Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF) stockread more...

The latest market developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity; Sunation Energy (NASDAQ:SUNE) is positioned at the center of Suniva’s $835 million financing and planned expansion to 5.5 GW of U.S. solar-cell capacity; and The OLB Group (NASDAQ:OLB) is attempting to build a rebound momentum after recently hitting a new 52-week low and, yes, I know that’s a sixth company.

Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.read more...

U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.read more...

The market is once again rewarding investors who know where to look for catalysts, bioAffinity Technologies (NASDAQ:BIAF), NeOnc Technologies Holdings (NASDAQ:NTHI), Opus Genetics (NASDAQ:IRD), Eos Energy Enterprises (NASDAQ:EOSE) with Google (NASDAQ:GOOG), and Scorpio Gold (NASDAQ:SGLD) each have a distinctly different catalyst driving their narratives.